Group 1: Stock Performance and Investor Relations - The company's stock price has recently declined due to various factors, and management is considering measures such as share buybacks and stock purchases to boost investor confidence [1][2] - The company has implemented multiple strategies, including cash dividends and stock incentive plans, to enhance investor trust [2] Group 2: Project Development and Market Potential - The polyethersulfone project is currently in the R&D phase and has not yet reached mass production; future revenue projections will be disclosed in regular reports [2] - The company has been recognized by the Ministry of Industry and Information Technology and the National Medical Products Administration for its innovative biomedical materials [2] Group 3: Sales and Marketing Strategies - The company emphasizes the need for ongoing investment in sales expenses to promote new technologies and products in the clinical setting [3] - The blood purification industry is still in its early stages, necessitating significant market promotion efforts [3] Group 4: Health Management Initiatives - The company is actively exploring new business areas related to metabolic cardiovascular diseases and health management, responding to national health initiatives [4] - A major clinical study on plasma adsorption in stroke patients has been initiated, showing promising preliminary results [4] Group 5: Product Pricing and Market Impact - The blood purification products have not yet been included in centralized procurement, but there is a possibility for future inclusion, which could affect pricing and profit margins [5] - The company is preparing for potential impacts from centralized procurement policies, focusing on quality competition rather than just price [5] Group 6: Research and Development Focus - The company invests over 200 million annually in R&D, having registered 11 new products since 2022 [11] - The R&D strategy includes developing various blood purification products targeting different diseases, maintaining a competitive edge in the industry [10] Group 7: International Expansion and Market Strategy - The company is prioritizing international market expansion, having achieved product entry in 98 countries and established a presence in over 2000 hospitals abroad [18] - The focus is on academic promotion and collaboration to enhance global awareness of blood adsorption technology [18] Group 8: Regulatory and Policy Developments - Recent policy changes have officially included blood purification and plasma adsorption in the medical insurance reimbursement list, which is expected to accelerate product promotion [19] - The company is committed to timely and accurate information disclosure to protect investor rights [19]